How Does Retatrutide Work? The Triple Agonist Mechanism

Retatrutide works by switching on three hormone receptors with one weekly shot: GLP-1 and GIP, which cut appetite and help the pancreas release insulin when blood sugar is high, and glucagon, which appears to push the liver to burn more of its fat. In Lilly's TRIUMPH-1 trial, people on the 12 mg dose lost 28.3% of their body weight on average over 80 weeks. A straight answer to "how does retatrutide work" also has to say which parts were measured in people and which come from lab dishes and animals.

Most explanations stop at the receptor list. The claims built on it don't have equal backing: "lowers blood sugar" has a Phase 3 trial behind it, "cuts appetite" leans on the tirzepatide and semaglutide labels, and "burns more calories" has only animal work so far.

How does retatrutide work in the body?

Lilly describes retatrutide as a single molecule that activates the body's receptors for GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1) and glucagon. Those are the docking points for three hormones your body already releases around meals.

It's given as a shot under the skin once a week, and it lingers. According to Lilly's medical information page, blood levels peak 12 to 72 hours after a dose, and the 2022 Phase 1b trial in The Lancet put the half-life at about 6 days. A fatty acid chain bolted onto the peptide (a C20 fatty diacid) lets it bind to albumin, the most common protein in blood, which slows its removal. Tirzepatide carries the same kind of C20 tail, and its FDA label says it does the same job there. Our retatrutide half-life page works through what that means for missed doses and stopping.

That's also where the "GLP-3" nickname comes from. Semaglutide acts on one of these receptors, tirzepatide on two and retatrutide on three, so headline writers kept counting. Lilly calls the label scientifically inaccurate and prefers "triple agonist". The GLP-3 page covers the name.

What each of the three receptors does

The three natural hormones have separate jobs that overlap, and retatrutide doesn't hit their receptors equally hard.

Hormone roles and potency figures come from Lilly's medical information page, which cites the 2022 Cell Metabolism discovery paper. The liver figures come from the 2024 Nature Medicine substudy.

So the balance is lopsided on purpose. Retatrutide leans hard on the GIP receptor and treats the other two more gently. The 2022 Cell Metabolism paper described the GLP-1 and glucagon sides as roughly balanced with each other, with more GIP activity on top.

The appetite part is the best understood, but mostly through other drugs. The tirzepatide and semaglutide labels both say each drug lowers calorie intake, likely by acting on appetite, and that GLP-1 receptors sit in brain areas that control hunger. That's class evidence, not retatrutide data. Tirzepatide's label also says the case for GIP adding to that appetite effect comes from studies outside people.

Why add glucagon if it raises blood sugar?

Glucagon's best-known job is to push blood sugar up, so putting it in a diabetes drug looks backwards. The trials say the combination still lowers sugar. In TRANSCEND-T2D-1, published in The Lancet in 2026, A1C fell by up to 2.0 points on 9 mg from a starting average of 7.9% over 40 weeks, against 0.8 points on placebo, with no severe hypoglycemia. In TRIUMPH-3, high blood sugar was reported as a side effect in 3.9% on 9 mg and 3.1% on 12 mg, against 13.4% on placebo.

Our read: in people, the insulin push from the GLP-1 and GIP sides outweighs glucagon's pull on blood sugar.

People in TRANSCEND-T2D-1 took no other diabetes drugs. The tirzepatide label (class evidence) says low blood sugar gets more likely with insulin or a sulfonylurea, so ask your doctor about those doses first.

The case for adding glucagon rests on two other effects. In Lilly's 2022 Cell Metabolism paper, retatrutide cut weight in obese lab animals partly by raising energy use on top of lower food intake. That result is from animals, and it hasn't been shown in people.

The second effect is on the liver, and here there is human data. In the fatty liver substudy of the Phase 2 obesity trial (Nature Medicine, 2024), liver fat fell by 86.0% on 12 mg at 48 weeks, relative to where it started, against 4.6% on placebo. Blood levels of beta-hydroxybutyrate, a marker of fat burning, rose 2 to 3 fold in a dose-related pattern at 4 mg and above, and nobody developed ketoacidosis. A score of insulin resistance (HOMA2-IR) dropped by up to 69.3% at 48 weeks.

The authors were careful about cause. They wrote that the bigger liver fat drop compared with GLP-1 drugs and tirzepatide may come from the extra weight loss, from glucagon acting directly on the liver, or both. Near-maximal liver fat loss arrived at about 20% weight loss. More on that in retatrutide for fatty liver.

What's proven in people, and what isn't

Popular explanations of reta mix the evidence together. Here it is sorted by source, as of September 2026:

The calorie-burning row is the one worth watching. Lilly ran a Phase 1 study in 85 people with obesity (NCT06313528) that measured calorie intake at lunch and dinner, 24-hour energy use and sleeping metabolic rate on retatrutide versus placebo. ClinicalTrials.gov shows it finished on August 26, 2025. When we checked on September 29, 2026, no results had been posted.

Our read: until that study reports, "reta burns more calories" is a hypothesis from animal work, and eating less is the better-supported part of the mechanism. If a video or seller page tells you how many extra calories it burns a day, ask where the number came from.

Does retatrutide work? What the trials measured

Yes, at the level trials can measure. Every Phase 3 obesity trial reported so far beat placebo by a wide margin, and the loss grew with dose. The top dose's results by trial:

All four are Lilly's topline releases using the efficacy estimand (as if everyone had stayed on treatment). As of late September 2026, none of them has a full journal paper.

Dose matters. In TRIUMPH-1, the 4 mg group lost 19.0% and the 9 mg group 25.9%, against 28.3% on 12 mg. The effect also outlasts a single shot: in Lilly's first human study, weight stayed lower up to day 43 after one dose, the Cell Metabolism paper reported.

Why doesn't reta work for me?

Some people see much less than the averages above, and the trials themselves point to the usual reasons.

The dose is still climbing. In every Phase 3 trial so far, people on retatrutide started at 2 mg and stepped up every 4 weeks. By that schedule, people aiming for 12 mg went through 2, 4, 6 and 9 mg first and didn't reach 12 mg until week 17. Low doses do far less: in the Phase 2 NEJM trial, people kept on 1 mg averaged 8.7% loss at 48 weeks, against 24.2% on 12 mg.

In TRIUMPH-1, 62.5% of people on 12 mg lost 25% or more of their weight, which means about 4 in 10 on the top dose didn't reach that mark. In the Phase 2 NEJM trial, though, 100% of the people analyzed on 12 mg had lost at least 5% by week 48. Losing nothing after months on 12 mg is outside what that trial saw, and worth raising with a doctor.

People with type 2 diabetes lose less on average: 20.8% on 12 mg in TRIUMPH-2, against 28.3% for people without diabetes in TRIUMPH-1. Those are separate trials, but the gap is wide.

The vial may not hold retatrutide. In a September 14, 2026 alert, Australia's TGA said it had tested a vial sold as retatrutide after a user was hospitalized. It found no retatrutide, and undeclared semaglutide at about 8 times the level in approved products. Lilly says nothing sold outside its trials can be checked for purity or dose. If you're weighing a vial from a peptide seller, our retatrutide for sale page explains what a batch-specific test report checks and what it can't prove.

Where the side effects fit the mechanism

The stomach side effects follow from the GLP-1 side. Slower stomach emptying helps you feel full, and it also brings nausea. Tirzepatide's label says the delay is largest after the first dose and fades over time, which is class evidence. Retatrutide's numbers fit that picture: in TRIUMPH-1, 42.4% of people on 12 mg had nausea against 14.8% on placebo, and in TRANSCEND-T2D-1 the stomach effects came mainly during dose increases.

Two effects are less explained. Heart rate rose with dose in the Phase 2 NEJM trial, peaked at 24 weeks and then declined. Burning or oversensitive skin (dysesthesia) hit 12.5% of people on 12 mg in TRIUMPH-1, against 0.9% on placebo; tirzepatide's label lists it at 0.4% or less. Nobody has published why retatrutide causes more of it. The full list is on the side effects page.

The next test of the mechanism is head to head. TRIUMPH-5 compares retatrutide with tirzepatide in about 800 adults with obesity, with primary completion estimated for November 2026, which makes it the closest test yet of what glucagon adds on top of tirzepatide's two receptors. Until then, retatrutide vs tirzepatide compares the two across separate trials.